Baxiva is developing the first K-antigen-targeting vaccine to prevent E. coli infections, offering the highest level of protection against UTIs and systemic infections.
Location: Switzerland
Total raised: $3.38M
Investors 2
| Date | Name | Website |
| 30.01.2026 | Venture Ki... | venturekic... |
| 06.09.2025 | CARB-X | carb-x.org |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.02.2026 | - | $187.94K | Venture Ki... |
| 17.11.2025 | Grant | $187.94K | - |
| 22.08.2025 | - | $3M | CARB-X |
Mentions in press and media 4
| Date | Title | Description |
| 23.02.2026 | Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine | Urinary tract infections are among the most common bacterial diseases globally, and most cases are caused by E. coli. These infections can lead to serious complications, including sepsis, and cause more than 80,000 deaths each year in the ... |
| 17.11.2025 | InnoBooster supports six early-stage startups with CHF 900’000 | InnoBooster is an initiative of the Gebert Rüf Stiftung (GRS) designed to support university students that have already entered the second stage of the Venture Kick program with up to CHF 150,000 for a maximum of 1.5 years. This funding al... |
| 12.09.2025 | Newcomers in the spotlight | The ETH Pioneer Fellowship Programme has been in existence for 15 years, empowering entrepreneurs at the university to turn research results into successful start-ups. For ten years, the programme has been staging the 3Pi Pitch Competition... |
| 22.08.2025 | Baxiva secures $3 million to advance antibacterial vaccines | Escherichia coli (E. coli) is the leading cause of urinary tract infections, a frequent cause of neonatal sepsis, and is among the leading causes of antimicrobial resistance-associated deaths globally. One approach to tackle this is with m... |